grinboss

Pfizer

PFE

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

At $28.06 (close on November 18) and with the other assumptions at their starting point, Pfizer's sales would need to grow 5.7% a year for ten years; over its last decade, the median was 1.0%. Value it with your own assumptions.

Its accounts, year by year

Year endSalesGrowthMargin
12/201548,851—22.2%
12/201652,8248.1%19.4%
12/201752,546−0.5%27.4%
12/201840,825−22.3%14.3%
12/201940,9050.2%33.2%
12/202041,6511.8%22.2%
12/202181,28895.2%32.9%
12/2022101,17524.5%36.4%
12/202359,553−41.1%6.4%
12/202463,6276.8%18.8%
12/202562,579−1.6%17.6%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Pfizer files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 6.8% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 17.6% of sales.
  • Working capital needed to grow: $1.3 per $100 of new sales.
  • Capital spending: 4.2% of sales.
  • Stock pay to employees: 1.8% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • Its share price moves less than the market: a five-year beta of 0.43; the median is 0.94.
  • It is one of the big ones: it sells $62.6 billion a year; the median of grinboss companies is $15.1 billion.
  • It ties up little money as it grows: $1 for every $100 of new sales; the median is $2.

Against

  • Its margin jumps from one year to the next: 11.2 points on average, and up to 30.0 in a single year; the median is 2.8 points.
  • Its margin has fallen over these years, from 22% to 18%.
  • It owes a lot: its net debt equals 3.1 years of operating profit plus depreciation and amortization (EBITDA), more than the median (1.5).
  • Its sales fell in 4 of the last 10 years: it is an uneven business.

Next results: February 2, 2027.

Other companies in its sector (Health Care)

Insulet Corporation (PODD) · Regeneron Pharmaceuticals (REGN) · ResMed (RMD) · Revvity (RVTY) · Solventum (SOLV) · Steris (STE) · Stryker Corporation (SYK) · Bio-Techne (TECH) · All companies

Loading the model…